Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (81-90 of 148) with videos related to

Pageof 15
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsAllan Lipton, Robert Uzzo, Robert J Amato, et al.
Cancer|May 7, 2008
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidAllan Lipton, Richard Cook, Fred Saad, et al.
Cancers|July 30, 2020
Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone MetastasesSoraia Lobo-Martins, Arlindo R Ferreira, André Mansinho, et al.
Urology|September 11, 2007
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancerMatthew R Smith, Richard J Cook, Robert Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancerRichard J Cook, Robert Coleman, Janet Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases statusLuis Costa, Laurence M Demers, A Gouveia-Oliveira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myelomaJames R Berenson, Bruce E Hillner, Robert A Kyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Serum osteoprotegerin levels in healthy controls and cancer patientsAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
Journal of Bone Oncology|March 4, 2022
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approvalBenoit Cadieux, Robert Coleman, Pegah Jafarinasabian, et al.
Cancer Investigation|November 22, 2002
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronateAllan Lipton, E Small, Fred Saad, et al.
Pageof 15

Showing results (81-90 of 148) with videos related to

Sort By:
Pageof 15
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsAllan Lipton, Robert Uzzo, Robert J Amato, et al.
Cancer|May 7, 2008
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidAllan Lipton, Richard Cook, Fred Saad, et al.
Cancers|July 30, 2020
Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone MetastasesSoraia Lobo-Martins, Arlindo R Ferreira, André Mansinho, et al.
Urology|September 11, 2007
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancerMatthew R Smith, Richard J Cook, Robert Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancerRichard J Cook, Robert Coleman, Janet Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases statusLuis Costa, Laurence M Demers, A Gouveia-Oliveira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myelomaJames R Berenson, Bruce E Hillner, Robert A Kyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Serum osteoprotegerin levels in healthy controls and cancer patientsAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
Journal of Bone Oncology|March 4, 2022
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approvalBenoit Cadieux, Robert Coleman, Pegah Jafarinasabian, et al.
Cancer Investigation|November 22, 2002
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronateAllan Lipton, E Small, Fred Saad, et al.
Pageof 15